Lung cancer accounts for more cancer deaths per year than any other cancer and the majority of patients have locally advanced or metastatic disease at initial clinical presentation. Non-small cell lung cancer (NSCLC) is a heterogeneous disease with a wide diversity of genomic subtypes in which mutations or abnormal gene expression profiles drive cancer cell growth. Approximately 20-25% of all metastatic non-squamous (m) NSCLCs harbour oncogenic driver mutations such EGFR, ALK, ROS1. But there an increasing number of genomic alterations in mNSCLC that are not adequately identified by current diagnostic testing.

Comprehensive genomic profiling (CGP) has the capacity to identify actionable genomic alterations missed by current testing, potentially allowing patients to access personalised treatment with targeted drugs. The ASPiRATION study will evaluate the clinical impact of CGP on the management of mNSCLC and assess the feasibility of implementation of CGP nationally. The study will be discussed and expected commencement and timelines.

Assoc. Professor Nick Pavlakis Senior Staff Specialist, Royal North Shore Hospital, and Genesis Care. President, The Clinical Oncology Society of Australia (COSA) Board Chair, The Thoracic Oncology Group of Australasia (TOGA) Senior Staff Specialist, Department of Medical Oncology

A/Professor Nick Pavlakis is medical oncologist with more than 20 years’ experience in the oncology field, including clinical and translational research. He trained in anti-angiogenic drug development and has an interest in new drug development and evaluation of drug resistance and biomarkers in lung cancer, mesothelioma, and GI malignancies. He is study lead of several national and international co-operative group studies. He is a deputy chair of the IASLC CME Committee and has served on Faculty of the WCLC.